Overview

Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Status:
Completed

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

Summary

This study will investigate efficacy and safety of vildagliptin in patients with low baseline levels starting at an HbA1C level of 6.5% to support convenient early intervention with combination therapies. In parallel, morning and evening dosing will be evaluated in this patient population for the first time.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Metformin
Vildagliptin